SCHEMBL3668804

SCHEMBL3668804

O=C(Nc1ccc(-c2ccccc2)cc1)Nc1cc(Cl)c(O)c(Cl)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 10/20 0.61
MEN1 O00255 3/20 0.56
MAPT P10636 3/20 0.56
KMT2A Q03164 3/20 0.56
NPC1 O15118 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
LMNA P02545 1/20 0.56
HTT P42858 1/20 0.56
GRIK1 P39086 1/20 0.56
RAB9A P51151 2/20 0.56
NPSR1 Q6W5P4 2/20 0.56
KDR P35968 1/20 0.55
MGLL Q99685 1/20 0.53
KDM4E B2RXH2 1/20 0.53
POLB P06746 1/20 0.53
GAA P10253 1/20 0.53
MAPK1 P28482 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
SMO Q99835 1/20 0.52
EPHX1 P07099 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4342381 0.90 KMT2A (0.68) CNR1MEN1MAPTKMT2ANPC1
SCHEMBL3681281 0.88 MGLL (0.73) CNR1MEN1MAPTKMT2ANPC1
SCHEMBL4350770 0.83 MEN1 (0.67) MEN1MAPTKMT2ANPC1SMN1; SMN2
SCHEMBL4358553 0.83 MEN1 (0.71) CNR1MEN1MAPTKMT2ANPC1
SCHEMBL6567241 0.82 EPHX1 (0.59) MEN1MAPTKMT2ANPC1SMN1; SMN2
SCHEMBL6567563 0.82 CA12 (0.54) MEN1MAPTKMT2ANPC1SMN1; SMN2
SCHEMBL20557568 0.81 CNR1 (0.81) CNR1GRIK1
SCHEMBL5359926 0.80 SMN1; SMN2 (0.77) CNR1MAPTKMT2ANPC1SMN1; SMN2
SCHEMBL6567652 0.79 NPC1 (0.66) CNR1MEN1MAPTKMT2ANPC1
SCHEMBL5594862 0.79 CXCR2 (0.62) CNR1MEN1MAPTKMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100234349-A1 PHARMACEUTICAL COMBINATIONS OF A NICOTINE RECEPTOR MODULATOR AND A COGNITIVE ENHANCER NEUROSEARCH A/S (DK) 2010-09-16 US claimed
US-20070142450-A1 Novel urea derivatives and their medical use NEUROSEARCH A/S (DK) 2007-06-21 US claimed
EP-2255848-A2 Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer NeuroSearch AS (DK) 2010-12-01 EP disclosed
US-20070142450-A1 Novel urea derivatives and their medical use NEUROSEARCH A/S (DK) 2007-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234349-A1 PHARMACEUTICAL COMBINATIONS OF A NICOTINE RECEPTOR MODULATOR AND A COGNITIVE ENHANCER CHRNA10, CHRNA4, CHRNA5 CNR1 99/4885MEN1 4874/4885MAPT 365/4885
US-20070142450-A1 Novel urea derivatives and their medical use ACHE, NMUR1, NMUR2 CNR1 32/4885MEN1 4363/4885MAPT 206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.